Antiangiogenic therapy for human pancreatic carcinoma xenografts in nude mice

World Journal of Gastroenterology

Volumn 11, Issue 3, 2005, Pages 447-450

  Jia, Lin ^a,c   Zhang, Mei Hua ^a   Yuan, Shi Zhen ^b   Huang, Wen Ge ^b  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

^c GUANGZHOU FIRST PEOPLE'S HOSPITAL   (China)

Author keywords

Angiogenesis inhibitors; Pancreatic carcinoma; TNP 470; Xenografts

Indexed keywords

FUMAGILLOL CHLOROACETYLCARBAMATE; GEMCITABINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG MECHANISM; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; METASTASIS; MONOTHERAPY; NONHUMAN; PANCREAS CARCINOMA; SURVIVAL RATE; TUMOR GROWTH; TUMOR VOLUME; WEIGHT REDUCTION; XENOGRAFT;

EID: 12344312012     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v11.i3.447     Document Type: Article

References (30)

1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin 2003; 53: 5-26
2. Kato H, Ishikura H, Kawarada Y, Furuya M, Kondo S, Kato H, Yoshiki T. Anti-angiogenic treatment for peritoneal dissemination of pancreas adenocarcinoma: a study using TNP-470. Jpn J Cancer Res 2001; 92: 67-73
3. Folkman J. Fundamental concepts of the angiogenic process. Curr Mol Med 2003; 3: 643-651
4. Hotz HG, Reber HA, Hotz B, Sanghavi PC, Yu T, Foitzik T, Buhr HJ, Hines OJ. Angiogenesis inhibitor TNP-470 reduces human pancreatic cancer growth. J Gastrointest Surg 2001; 5: 131-138
5. Konno H. Antitumor effect of the angiogenesis inhibitor TNP-470 on human digestive organ malignancy. Cancer Chemother Pharmacol 1999; 43(Suppl): S85-89
6. Shishido T, Yasoshima T, Denno R, Mukaiya M, Sato N, Hirata K. Inhibition of liver metastasis of human pancreatic carcinoma by angiogenesis inhibitor TNP-470 in combination with cisplatin. Jpn J Cancer Res 1998; 89: 963-969
7. Konno H, Tanaka T, Matsuda I, Kanai T, Maruo Y, Nishino N, Nakamura S, Baba S. Comparison of the inhibitory effect of the angiogenesis inhibitor, TNP-470, and mitomycin C on the growth and liver metastasis of human colon cancer. Int J Cancer 1995; 61: 268-271
8. Teicher BA, Dupuis NP, Robinson MF, Emi Y, Goff DA. Antiangiogenic treatment (TNP-470/minocycline) increases tissue levels of anticancer drugs in mice bearing Lewis lung carcinoma. Oncol Res 1995; 7: 237-243
9. Satoh H, Ishikawa H, Fujimoto M, Fujiwara M, Yamashita YT, Yazawa T, Ohtsuka M, Hasegawa S, Kamma H. Angiocytotoxic therapy in human non-small cell lung cancer cell lines-advantage of combined effects of TNP-470 and SN-38. Acta Oncol 1998; 37: 85-90
10. Furukawa T, Kubota T, Watanabe M, Kitajima M, Hoffman RM. A novel "patient-like" treatment model of human pancreatic cancer constructed using orthotopic transplantation of histologically intact human tumor tissue in nude mice. Cancer Res 1993; 53: 3070-3072
11. Weidner N. Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Breast Cancer Res Treat 1995; 36: 169-180
12. Kawarada Y, Ishikura H, Kishimoto T, Saito K, Takahashi T, Kato H, Yoshiki T. Inhibitory effects of the antiangiogenic agent TNP-470 on establishment and growth of hematogenous metastasis of human pancreatic carcinoma in SCID beige mice in vivo. Pancreas 1997; 15: 251-257
13. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002; 29(6 Suppl 16): 15-18
14. O'Reilly MS. The combination of antiangiogenic therapy with other modalities. Cancer J 2002; 8(Suppl 1): S89-99
15. Hayes AJ, Li LY, Lippman ME. Science, medicine, and the future. Antivascular therapy: A new approach to cancer treatment. BMJ 1999; 318: 853-856
16. Gervaz P, Fontolliet C. Therapeutic potential of the anti-angiogenesis drug TNP-470. Int J Exp Pathol 1998; 79: 359-362
17. Bhargava P, Marshall JL, Rizvi N, Dahut W, Yoe J, Figuera M, Phipps K, Ong VS, Kato A, Hawkins MJ. A Phase I and pharmacokinetic study of TNP-470 administered weekly to patients with advanced cancer. Clin Cancer Res 1999; 5: 1989-1995
18. Logothetis CJ, Wu KK, Finn LD, Daliani D, Figg W, Ghaddar H, Gutterman JU. Phase I trial of the angiogenesis inhibitor TNP-470 for progressive androgen-independent prostate cancer. Clin Cancer Res 2001; 7: 1198-1203
19. Stadler WM, Kuzel T, Shapiro C, Sosman J, Clark J, Vogelzang NJ. Multi-institutional study of the angiogenesis inhibitor TNP-470 in metastatic renal carcinoma. J Clin Oncol 1999; 17: 2541-2545
20. Ryschich E, Werner J, Gebhard MM, Klar E, Schmidt J. Angiogenesis inhibition with TNP-470, 2-methoxyestradiol, and paclitaxel in experimental pancreatic carcinoma. Pancreas 2003; 26: 166-172
21. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88: 277-285
22. Kakeji Y, Teicher BA. Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents. Invest New Drugs 1997; 15: 39-48
23. Kato T, Sato K, Kakinuma H, Matsuda Y. Enhanced suppression of tumor growth by combination of angiogenesis inhibitor O-(chloroacetyl-carbamoyl) fumagillol (TNP-470) and cytotoxic agents in mice. Cancer Res 1994; 54: 5143-5147
24. Teicher BA, Holden SA, Ara G, Korbut T, Menon K. Comparison of several antiangiogenic regimens alone and with cytotoxic therapies in the Lewis lung carcinoma. Cancer Chemother Pharmacol 1996; 38: 169-177
25. Herbst RS, Takeuchi H, Teicher BA. Paclitaxel/carboplatin administration along with antiangiogenic therapy in non-small-cell lung and breast carcinoma models. Cancer Chemother Pharmacol 1998; 41: 497-504
26. Jia L, Yuan SZ. Progress of treatment of advanced pancreatic carcinoma with gemcitabine. Shijie Huaren Xiaohua Zazhi 1999; 7: 985-986
27. Berlin JD, Catalano P, Thomas JP, Kugler JW, Haller DG, Benson AB 3rd. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 2002; 20: 3270-3275
28. Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15: 2403-2413
29. Jia L, Yuan SZ, Huang WG, Guo FF. Establishment of the model of human pancreatic carcinoma by surgical orthotopic implantation in nude mice. Guangzhou Medical J 2001; 32: 7-9
30. Jia L, Yuan SZ, Huang WG, Guo FF. Experimental study on Gemcitabine against model of pancreatic cancer by surgical orthotopic implantation in nude mice. Chin J Hepatobiliary Surg 2002; 8: 557-559